![](/images/graphics-bg.png)
Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Joint Authors
Smith, Daryn
Jacobs, John
Mulrenan, Heather
Lin, Ho-Sheng
Heilbrun, Lance K.
Yoo, George
Kafri, Zyad
Kucuk, Omer
Sukari, Ammar
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-05-10
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
To explore the safety and efficacy of gemcitabine and docetaxel (GEMDOC) in previously treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Patients and Methods.
Patients with advanced SCCHN previously pretreated with one or two lines of palliative chemotherapy were treated with gemcitabine and docetaxel until disease progression.
Results.
Thirty-six patients were enrolled, and 29 were response evaluable.
16 (55%) experienced clinical benefit (response or stable disease).
Six (21%) patients achieved partial response (PR), none achieved complete response (CR), and the overall response rate (ORR) was 21% (95% CI: 0.10–0.38).
Ten (28%) patients had stable disease.
The median response duration (RD) for the 6 PR patients was 3.2 months (80% CI: 2.0–6.1 months).
Median overall survival was 4.2 months (95% CI: 2.4–7.0 months).
Among the 33 treated patients: 13 (39%) patients had grade 3-4 anemia, 10 (30%) had grade 3-4 neutropenia.
Conclusion.
The study drugs were relatively safe, and the clinical benefit (PR + SD) rate was 55%.
However, the efficacy objective for this regimen was not met.
Given the good safety profile, further investigation of this regimen with the addition of a targeted agent may lead to better efficacy.
American Psychological Association (APA)
Kafri, Zyad& Heilbrun, Lance K.& Sukari, Ammar& Yoo, George& Jacobs, John& Lin, Ho-Sheng…[et al.]. 2012. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-450587
Modern Language Association (MLA)
Kafri, Zyad…[et al.]. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-450587
American Medical Association (AMA)
Kafri, Zyad& Heilbrun, Lance K.& Sukari, Ammar& Yoo, George& Jacobs, John& Lin, Ho-Sheng…[et al.]. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-450587
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-450587